ABSTRACT
Cerebrospinal fluid (CSF) amyloid beta 42 (Abeta 42 ) concentrations are decreased in patients with Alzheimer disease (AD). Consequently, low Abeta 42 is considered a positive biomarker for AD. Surprisingly, the mechanisms that underlie the decrease in CSF Abeta 42 remain speculative. Better understanding of this biomarker is an essential step to unravel AD pathophysiology and to develop and evaluate treatment. Therefore, we systematically examined the possible reasons for the decreased CSF Abeta 42 concentration in AD. Under normal conditions, Abeta 42 can be degraded by proteases, taken up by microglia, or cleared from the brain interstitial fluid across the blood brain barrier. Alternatively, it can be transported to the CSF and be cleared from there. Aggregation of Abeta 42 appears the most likely cause for the decreased CSF Abeta 42 concentration in AD: the aggregated state inhibits Abeta 42 from being transported from the ISF to the CSF. Evidence for other possibilities such as a decreased production of Abeta 42 , an increased proteolytic breakdown or microglial uptake of Abeta 42 , or an increased clearance of Abeta 42 to the blood, is -at bestscarce or even absent.
INTRODUCTION
The characteristic plaques of Alzheimer disease (AD) were discovered by Aloïs Alzheimer in 1906, but it was not until the 1980s that it was demonstrated that these plaques consist of the amyloid beta protein (Abeta). (1) (2) (3) The realization that this protein was the same as the protein accumulating in brains of patients with Down syndrome led to the discovery of the amyloid precursor protein (APP), located on chromosome 21, as the precursor protein of Abeta. (4) Subsequently, pathogenic mutations in the APP gene were discovered in familial AD. (5) (6) (7) (8) In the 1990s, Abeta could be measured in cerebrospinal fluid (CSF) for the first time. (9, 10) It was thereafter repeatedly shown that CSF Abeta 42 was decreased in AD. (11) (12) (13) (14) Nowadays, Figure 1 . The non-amyloidogenic and amyloidogenic pathways of APP processing APP is cleaved by either alpha-or betasecretase. Cleavage by alpha-secretase (the non-amyloidogenic pathway) generates sAPP-alpha and C83 (left). Cleavage by betasecretase (the amyloidogenic pathway) generates sAPP-beta and C99 (right). C83 is cleaved by gamma-secretase, generating AICD and p3 (not shown). C99 is also cleaved by gamma-secretase, generating AICD and Abeta (right). (See text for abbreviations.) Republished with permission of the American Society for Clinical Investigation, from reference no. 22; permission conveyed through Copyright Clearance Center, Inc.
it is an accepted biomarker for AD (15, 16) that is frequently used in clinical practice. (17, 18 ) Surprisingly, the cause of its decrease has not yet been fully elucidated, although several explanations have been offered: changes in Abeta generation or degradation may affect the CSF concentration, or an alteration in the solubility of Abeta42 may diminish clearance of Abeta42 from the interstitial fluid (ISF) to CSF. (11) (12) (13) (14) Determination of the CSF Abeta42 concentration in AD may be masked by its interaction with binding proteins, such as apolipoprotein J or E, or 11. E. Matsubara, B. Frangione and J. Ghiso, Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J. Biol. Chem. 270 (1995), pp. 7563-7567. View Record in Scopus | Cited By in Scopuan increased clearance of Abeta42 from CSF might explain the diminished levels of Abeta42 in the CSF of AD patients. (14) In spite of all these suggestions, the actual explanation for the decreased CSF Abeta42 in AD remains largely unidentified. Here, we will review the evidence for each of the proposed explanations to create a better understanding of the underlying mechanisms that lead to its recognition as an important AD biomarker. 42 Abeta 42 is produced by sequential cleavage of the amyloid precursor protein (APP) (Figure 1 ). APP is a membrane-bound protein whose function remains unclear, although a role in cell adhesion, cell growth and synaptogenesis has been suggested. (19, 20) APP can be cleaved by either alpha-or beta-secretase, and subsequently by gamma-secretase. Whether Abeta is produced from APP depends on which of these enzymes first cleaves APP.
ABETA 42 METABOLISM

Production of Abeta
Cleavage of APP by alpha-secretase at the plasma membrane or in the trans-Golgi network generates N-terminal fragment soluble APP-alpha (sAPP-alpha) and C-terminal fragment C83. (21) sAPPalpha is released into intracellular vesicles or extracellularly. C83 remains membrane-bound and is cleaved by gamma-secretase to produce p3 (Abeta17-40 and Abeta17-42/43) and APP intracellular domain (AICD) (CT57-59). (22-25) The latter is released into the cytoplasm. This pathway is called the nonamyloidogenic pathway since no Abeta40 or Abeta42 is produced.
Cleavage of APP by beta-secretase, the amyloidogenic pathway, takes place in the trans-Golgi network and in endosomes (20, 26) and generates Nterminal fragment soluble APP-beta and C-terminal fragment C 99 . sAPP-beta -just like sAPP-alpha -can be released into intracellular vesicles or extracellularly. C 99 remains membrane-bound and is subsequently cleaved by gamma-secretase to produce Abeta 42 or Abeta 40 and AICD. (22, 23) Cleavage by gamma-secretase takes place in the endoplasmatic reticulum, trans-Golgi network, endosomes, and for a small part at the plasma membrane. (26) Other isoforms of Abeta have been identified as well, with heterogeneity either at the C-or N-terminus of the peptide, but for clarity this review will be limited to Abeta 42 and Abeta 40 .
The amyloidogenic and non-amyloidogenic pathways are mutually exclusive. (22) APP molecules that are not cleaved at the cell membrane by alpha-secretase can be internalized by endocytosis and subsequently be cleaved by beta-secretase. (27) Redistribution of APP towards either the cell membrane or the cell interior can therefore influence the proteolytic pathway that APP undergoes. (22) Abeta 42 and Abeta 40 are either retained in cells or secreted into the ISF that surrounds the brain cells. (23) The equilibrium between intra-and extracellular Abeta 42 and Abeta 40 is in part regulated by active transport via the receptor for advanced glycation end products (RAGE), (28) a multiligand receptor of the immunoglobulin family. (29) 3.2. Degradation of Abeta 42 
Proteases
Several proteases can break down Abeta (both Abeta 42 and Abeta 40 
Microglia
Microglia are the macrophages of the brain. They take up soluble Abeta by macropinocytosis and possibly by binding of Abeta to the low-density lipoprotein receptorrelated protein (LRP). (34) Fibrillar forms of Abeta interact with the microglia cell surface and bind to the CD36 receptor expressed by microglia. CD36, a major pattern recognition receptor, mediates the microglial response to Abeta, leading to an intracellular signaling cascade that stimulates phagocytosis. (35) Ablation of microglia in mice led to an increase in soluble Abeta 40 and Abeta 42 , but had no influence on number and size of Abeta plaques. (36) This would support the idea that microglia are inefficient in degrading fibrillar Abeta. (34) However, others have found that upon activation, for example by cerebral ischemia or after vaccination with Abeta specific antibodies, microglia can degrade fibrillar Abeta. (37-39)
Clearance of Abeta 42
Abeta 42 and Abeta 40 can also be cleared from the extracellular compartment. It can be cleared from the ISF across the blood-brain barrier towards the circulation, or it can be transported from the ISF to the CSF, and be cleared from there. Alternatively, Abeta can be transported with the ISF or CSF to the peripheral lymphatic system (Figure 2 ).
Active transport of Abeta from ISF to systemic circulation
Both Abeta 42 and Abeta 40 can be removed from ISF to the blood by crossing the blood-brain barrier. The blood-brain barrier is primarily formed by endothelial cells in brain capillaries that are closely connected via tight junctions which exclude the transfer of many macromolecules from ISF into blood. (40) Astrocytes and pericytes may also play a role in the control of transport across the blood-brain barrier. Abeta 42 and Abeta 40 are primarily transported across the blood-brain barrier by LRP. (29) LRP is a multiligand lipoprotein receptor that mediates endocytosis of secreted proteins. It provides a rapid transport of brain-derived Abeta into the blood. (41) LRP-mediated transport is more efficient for Abeta 40 when compared to Abeta 42 (29, 31) , probably related to Abeta 40 's lower propensity to aggregate. Abeta 42 and Abeta 40 that is produced in the periphery can enter the brain ISF from the systemic circulation by active transport across the bloodbrain barrier via RAGE, which is expressed on the luminal surface of brain vessels. (29) 
Drainage of Abeta with ISF to lymphatics
One of the routes that ISF can follow is drainage along axonal tracts and through perivascular spaces. ISF travels along these perivascular spaces towards the surface of the brain and exits at the base of the skull, where it drains to regional lymph nodes in the neck. (42) The idea that Abeta is transported together with ISF along this pathway is supported by the fact that Abeta has been found in the basement membranes of capillary and arterial walls, but was not detectable further downstream in the walls of the carotid arteries. (43) 
Transport of Abeta from ISF to CSF
Another route for ISF is towards the CSF, where it constitutes 10-30% to the total CSF production. reaches the CSF via this route is uncertain. The glia limitans and the pia mater separate ISF from CSF in the subarachnoid space, however, the extent to which these layers block the passage of solutes and ISF into CSF is unknown. They may be fully permeable to fluid and small molecules, (29) but on the other hand, the presence of Abeta deposits in the glia limitans in AD suggests that transport of Abeta from ISF to CSF is limited in the subarachnoid compartment. (43) The concentration of Abeta 40 in CSF is about 6-fold greater than the concentration of Abeta 42 ; (45) (46) (47) in AD, the decreased concentration of CSF Abeta 42 makes the CSF Abeta 40 concentration at least 10-fold that of CSF Abeta 42 . (46-48) 
Absorption of Abeta from CSF to systemic circulation
Labeled Abeta injected into CSF of rats was detectable in blood a few minutes after injection. (49) From cell culture research it was inferred that Abeta can be absorbed from CSF at the choroid plexuses. (50) The endothelium of the blood vessels within the choroid plexus is leaky, but the epithelium between blood vessels and ventricular CSF contains tight junctions and forms the blood-CSF barrier (which should not be confused with the blood-brain barrier). Small molecules can enter or leave the brain. (40) Uptake of Abeta peptides at the choroid plexus was rapid and occurred as a non-diffusional, yet unclear uptake process. Efflux of Abeta from CSF to blood was favored over influx from blood into CSF. (50) In addition to the blood-CSF barrier, CSF drains to blood in the subarachnoid compartment, where CSF drains into the major venous sinuses via arachnoid granulations. Tight junctions in these granulations prevent passage of proteins, (51) and it is therefore unclear whether Abeta can be cleared from CSF to blood in this way.
Drainage of Abeta with CSF to lymphatics
The perineural sheath along the olfactory nerve represents another pathway of CSF drainage. The olfactory nerve fibers enter the nasal mucosa in the roof of the nasal cavity. At this point CSF drains from the perineural subarachnoid space into the extracellular matrix, where it is absorbed by blind-ended lymphatic capillaries, and drained to the regional lymph nodes that serve the nasopharynx. (44, 51) CSF also flows along the perineuronal sheaths of the cranial and spinal nerves to regional lymphatics. (40, 51, 52) It seems plausible that Abeta is cleared together with CSF via this pathway, but studies to confirm this are currently lacking.
WHY IS CSF ABETA 42 DECREASED IN ALZHEIMER DISEASE?
Several morphological changes that are related to the fate of the Abeta 42 peptide have been observed in AD. Upon post-mortem examination, Abeta plaques are found: diffuse plaques that contain only Abeta 42 , and classic plaques that consist of both Abeta 42 and Abeta 40 . (53, 54) In most AD cases, at least a mild degree of cerebral amyloid angiopathy is found as well, that consists of Abeta deposits in the walls of leptomeningeal and cortical arteries and less frequently in capillaries. (55) In contrast to the plaques, these vascular deposits contain mostly Abeta 40 . (56) The concentration of both Abeta 42 and Abeta 40 in the AD brain The numbers behind each mechanism refer to the corresponding section in the text.
is thus increased. (57, 58) However, the CSF concentration of Abeta 42 is decreased in AD patients, while the CSF Abeta 40 concentration is unaltered. (14, 48) We will focus on reasons why CSF Abeta 42 is decreased, while keeping in mind the other changes that occur in AD. Table 1 provides an overview of these reasons and the arguments supporting or contradicting them.
Is Abeta 42 production reduced?
Theoretically, a decreased concentration of Abeta 42 in CSF could simply be the result of a decreased production of Abeta 42 , for example by a reduction in the number of viable neurons that produce Abeta. However, several arguments make this unlikely. First, a decreased production does not logically connect to an increased Abeta 42 load in the brain. Second, if the production of Abeta 42 were decreased, the production of Abeta 40 would probably be decreased as well, since Abeta 42 and Abeta 40 likely share the same production pathway. This should then lead to a decreased CSF Abeta 40 concentration, which, however, is not observed in AD. Third, a decreased concentration of CSF Abeta 42 is also found in familial AD and in Down syndrome, disorders in which overproduction of Abeta 42 has been clearly demonstrated. (59) (60) (61) (62) Decreased Abeta 42 thus exists despite overproduction, which implies that factors other than production play a role in causing the decreased CSF concentration.
An alternative theory is that Abeta 42 secretion from the cell is decreased, leaving less Abeta 42 available in the ISF for transport to the CSF. Although intraneuronal Abeta aggregation has been described in triple transgenic mouse models, (63) Abeta predominantly accumulates extracellularly in human AD. This implies that the secretion of Abeta from the cell to the exterior is not diminished and that a decreased secretion of Abeta 42 by the cell is unlikely to be the cause of the decreased CSF Abeta 42 concentration.
Supporting these arguments against a decreased production or secretion of Abeta 42 is a study showing that the production rate of Abeta 42 and Abeta 40 , as measured in CSF using labeled Abeta 42 and Abeta 40 , did not differ between controls and AD patients. (64) 
Is Abeta 42 degradation increased?
It can be hypothesized that an increase in proteolytic breakdown of Abeta 42 leads to a decreased CSF Abeta 42 concentration. However, an increase in proteolytic breakdown would clear the brain from not only Abeta 42 , but also from Abeta 40 (65) and would preclude formation of plaques. Understandably, research has focused on finding defects in proteolytic degradation of Abeta rather than overactivity of these proteases to explain the elevated cerebral levels of Abeta. (32, 33) It appears that levels of neprilysin decrease with aging (66) and that low levels of neprilysin make certain brain areas more vulnerable to Abeta deposition, (67, 68) suggesting that proteolytic activity is decreased rather than increased.
Is microglial uptake of Abeta 42 increased?
An increased microglial uptake of Abeta 42 could be hypothesized to lead to the decreased CSF Abeta 42 concentration by leaving less Abeta 42 available in the ISF for transport to the CSF. Activated microglia are found in the vicinity of compact Abeta plaques, (69) however, the very presence of these plaques shows that microglial uptake of Abeta is insufficient to lead to a lower-than-normal concentration of Abeta in ISF. On the contrary, it has been suggested that with age, microglia become dysfunctional and less able to clear Abeta 42 . (34, 70, 71 ) Thus, it is unlikely that microglial ability to degrade Abeta is increased in AD.
Is Abeta 42 clearance affected?
Changes in the clearance of Abeta from either ISF or CSF (the solid arrows in Figure 1 ) can influence the Abeta concentration. An increased transport of ISF or CSF, containing Abeta, to the lymphatics will not affect the Abeta concentration.
Is clearance of Abeta 42 from ISF increased?
An increased clearance of Abeta 42 from ISF to blood across the blood-brain barrier would leave a smaller amount of Abeta 42 Another argument against an increased transport of Abeta 42 across the blood-brain barrier is the lack of an increase in plasma Abeta 42 concentration. Increased transport of Abeta 42 to the blood should result in an increase in the plasma concentration of Abeta 42 -assuming that the peripheral breakdown and elimination of Abeta 42 are not increased in AD. Reports on the plasma Abeta 42 concentration in AD patients are contradictory, but a clear increase has not been shown. (73, 74) Finally, enhanced clearance of Abeta 42 from the ISF is incompatible with the increased Abeta load that is found in AD brains. In summary, it cannot be concluded that transport across the blood-brain barrier is increased. 
Perivascular deposition of Abeta
Signs that Abeta 42 is deposited before it reaches the CSF are present: Abeta deposits are found in the walls of the cerebral vasculature and in the glia limitans in the subarachnoid compartment. (43, 77, 78) The deposits in the cerebral vasculature consist mostly of Abeta 40 , and to a lesser extent of Abeta 42 . (56) In clinically diagnosed cerebral amyloid angiopathy, a decreased CSF Abeta 40 concentration was found. (79) This suggests that perivascular Abeta deposition can indeed lead to a decreased CSF Abeta concentration. However, cerebral amyloid angiopathy found in AD is mostly mild to moderate, (55) and the amount of Abeta 42 that is deposited in the cerebral vasculature is presumably insufficient to be the sole explanation for the decreased CSF Abeta 42 concentration.
Parenchymal aggregation of Abeta
Aggregation of Abeta 42 into insoluble deposits may be a reason why Abeta 42 Uptake of Abeta 42 from the CSF was inferred from research in cell culture that used Abeta 40 as a model compound for all Abeta species. (50) Theoretically, this process could be upregulated in AD, resulting in more Abeta 42 to be transported from the CSF into the blood. Since the CSF Abeta 40 concentration is unaltered, this upregulation should then selectively affect Abeta 42 and not Abeta 40 . Research to confirm this is currently lacking. In contrast, research in rats suggests that uptake of Abeta from the CSF decreases with aging. (82) Furthermore, the increase in the plasma concentration of Abeta 42 that would be expected if upregulated efflux was the case (and peripheral elimination of Abeta was unaltered), has not been shown convincingly. (73, 74) Therefore it seems unlikely that an increased clearance of Abeta 42 from the CSF is the cause of the decreased CSF Abeta 42 concentration in AD.
PERSPECTIVE
We have reviewed a number of possible mechanisms that could theoretically explain the typical observation of a decreased CSF Abeta 42 concentration in AD. It appears very difficult to understand the decrease in CSF Abeta 42 found in AD. Based on simple but systematic reasoning, a number of theoretical mechanisms can be formulated, however, most of these do not concur with the premise that there is an increased Abeta load in the AD brain, and that the decreased CSF Abeta 42 is accompanied by an unaltered CSF Abeta 40 concentration. Furthermore, many of these theoretical mechanisms are contradicted by (often fragmented) findings from research. For example, a decreased production of Abeta 42 has not been shown: production rates were comparable between controls and AD patients. Increased proteolytic breakdown of Abeta is unlikely, since available evidence suggests a decrease in proteolytic activity rather than an increase. An increased microglial uptake of Abeta 42 is not supported, instead, a decrease in activity with aging is found. Increased clearance of Abeta 42 from either ISF or CSF has not been reported; rather, decreases in clearance have been suggested.
What, in our opinion, remains as the most plausible cause of the decreased Abeta 42 concentration in CSF is Abeta 42 aggregation. Abeta 42 is known to aggregate easily and once aggregates have been formed, transport of these aggregates from the ISF to the CSF may be seriously impaired. Abeta 40 has different properties and is not as prone to aggregation, which may explain why less Abeta 40 is found deposited in the AD brain, and why CSF concentrations of Abeta 40 are unaltered.
Until novel mechanistic insights with respect to the different steps in Abeta metabolism are obtained, this remains currently the most satisfying explanation for the observed Abeta changes in AD. Our systematic approach may have provided a framework against which the currently available knowledge from research can be laid out, as pieces of a puzzle. In this way, CSF Abeta 42 can be much more than a diagnostic test with an empirical cut-off value for use in clinical settings. Better understanding of this biomarker may be the key to a better understanding of the disease.
